Document is current

Article History

Received: 10 January 2025

Accepted: 2 February 2025

First Online: 20 February 2025

Declarations

:

: Maggie Banys-Paluchowski: Honoraria for lectures and advisory role from: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, resitu, Pierre Fabre, ExactSciences, Menarini Stemline; Study support: EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, ExactSciences, Claudia von Schilling Foundation for Breast Cancer Research, Ehmann-Stiftung Savognin; Travel reimbursement: Eli Lilly, ExactSciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche Hans-Christian Kolberg: Honorare for lectures and advisory role from Pfizer, Seagen, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, TEVA, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo and MSD, Travel support from Carl Zeiss meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Gilead, Roche, Onkowissen and Tesaro; Stock ofTheraclion SA. Jana de Boniface: Honoraria for lectures for Astra Zeneca, Lily and Novartis Nina Ditsch: Advisory Boards: Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, Exact Sciences, Lectures: AstraZeneca, Daiichi-Sankyo, Exact Sciences, Pierre-Fabre, I-Med-Institute, Merit-Medical, pfm medical ag, Medi-Seminar GmbH, Roche, Lilly, Pfizer, Gilead, Novartis, Manuscript: pfm medical ag, Trial funding: Gilead, BZKF, Other: Onkowissen, Jörg Eickeler Kongress, if-Kongress Vesna Bjelic-Radisic: Honoraria for lectures and advisory role from: Roche, Novartis, Pfizer, pfm, Eli Lilly, AstraZeneca, Gilead, Sirius Medical, Pierre Fabre, Mammotome, Travel reimbursement: Pierre Fabre, Pfizer Maria Luisa Gasparri: Consultant for Merit Medical Nikolas Tauber: Honoraria for lectures and participation in advisory boards: Novartis, ExactSciences, Georg Thieme Verlag. Support for attending meetings from Astra Zeneca Marc Thill: Advisory Board: Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Biom ‘Up, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm Medical, Pierre-Fabre, Roche, Seagen, Sirius Medical, Sysmex; Manuscript support: Amgen, ClearCut, Clovis, Lilly, Organon, pfm medical, Roche, Servier; Travel expenses: Amgen, Art Tempi, AstraZeneca, Clearcut, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, Hexal, I-Med-Institute, Lilly, MSD, Neodynamics, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, Seagen, ZP Therapeutics; Congress support: Amgen, AstraZeneca, Celgene, Daiichi Sanyko, Gilead, Hexal, Lilly, Neodynamics, Novartis, Pfizer, Pierre Fabre, Roche, Sirius Medical; Lecture honoraria: Agendia, Amgen, Art Tempi, AstraZeneca, Clovis, Connect Medica, Eisai, Endomag, Exact Sciences, Gedeon Richter, Gilead Science, GSK, Hexal, I-Med-Institute, Jörg Eickeler, Laborarztpraxis Walther et al., Lilly, Medscape, MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, StreamedUp, Stemline, Sysmex, Vifor, Viatris, ZP Therapeutics; Trial Funding: Endomag, Exact Sciences; Trial honoraria: AstraZeneca, Biom’Up, CairnSurgical, Clearcut, Neodynamics, Novartis, pfm medical, Roche, RTI Surgical. Other authors declare no competing interests.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Aachen, Germany (Date: April 28, 2020, Number: EK 013/20).

: Informed consent was obtained from all individual participants included in the study.